Sunshine Heart benefits from negative NEJM article, says Piper Jaffray Piper Jaffray views the NEJM article relating to an increase in clotting after implantation of Thoratec's (THOR) Heartmate II as mildly positive for Sunshine Heart (SSH). Piper believes attention to LVAD thrombosis rates could help remind the medical and investment community of the potential for a low clotting rate with the Sunshine Heart device. The firm reiterates an Overweight rating on Sunshine Heart with a $14 price target.
Thoratec growth sustainable despite NEJM article, says Leerink Leerink says a number of variables impact LVAD thrombus rates, which likely makes the New England Journal of Medicine article on Thoratec's (THOR) HeartMate II inconclusive. The firm continues to believe mid-teens LVAD market growth is sustainable over the next few years since the study sample is still relatively small. The firm says shares of Thoratec could trade down temporarily on the article while shares of competitor HeartWare (HTWR) shares could react positively. Leerink has an Outperform rating on both names.
NEJM study says Thoratec heart pump could increase rate of thrombosis A study published in the New England Journal of Medicine Wednesday stated, "We observed an apparent increase in the rate of device thrombosis among patients who received the HeartMate II left ventricular assist device, as compared with preapproval clinical-trial results and initial experience. We investigated the occurrence of pump thrombosis and elevated lactate dehydrogenase levels, LDH levels presaging thrombosis, and outcomes of different management strategies in a multi-institutional study...The rate of pump thrombosis related to the use of the HeartMate II has been increasing at our centers and is associated with substantial morbidity and mortality." The HeartMate II is made by Thoratec. Reference Link